Acute and intermittent management of increased muscle tone associated with spasticity.
Adults: PO Initiate therapy with a 4 mg dose, increasing the dose gradually in 2 to 4 mg increments to optimum effect. The dose can be repeated at 6- to 8-h intervals as needed (max, 3 doses in 24 h not to exceed 36 mg/day).
An alpha-2 adrenergic receptor agonist that may reduce spasticity by increasing presynaptic inhibition of motor neurons.
Coadministration of ciprofloxacin or fluvoxamine; hypersensitivity to any component of the product.
CNS: anxiety, depression, dizziness , sedation, weakness , dyskinesia, hallucinations, nervousness .
EENT: blurred vision, pharyngitis, rhinitis.
CV: hypotension, bradycardia .
GI: abdominal pain , diarrhea, dry mouth , dyspepsia, constipation , hepatocellular injury, increased liver enzymes , vomiting.
GU: urinary frequency .
Derm: rash, skin ulcers, sweating .
MS: back pain, myasthenia, paresthesia .
Misc: fever, speech disorder.
ACE inhibitors (eg, lisinopril)
Pharmacologic effects of ACE inhibitors may be increased, possibly resulting in severe hypotension.
The time to reach acetaminophen peak concentrations may be delayed.
Plasma levels of tizanidine may be elevated, increasing the adverse reactions.
Use with caution; do not administer with other alpha-2 adrenergic agonists (eg, clonidine).
Coadministration with tizanidine is contraindicated. Tizanidine plasma concentrations may be elevated, increasing the risk of adverse reactions (eg, hypotension, sedation).
CYP1A2 inhibitors (eg, acyclovir, antiarrhythmic agents [eg, amiodarone, mexiletine, propafenone, verapamil], cimetidine, famotidine, fluoxetine, hormonal contraceptives, quinolone antibiotics [eg, norfloxacin], ticlopidine, zileuton)
Tizanidine plasma levels may be elevated, increasing pharmacologic effects and adverse reactions.
Therapeutic Classification: antispasticity agents (centrally acting)
Pharmacologic Classification: adrenergics
Absorption: Completely absorbed after oral administration but rapidly metabolized, resulting in 40% bioavailability.
Distribution: Widely distributed.
Metabolism/Excretion: 95% metabolized by the liver.
Half-life: 2.5 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal